CoChat

The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

Open access
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., Giorgino, F. · 2024 · Journal of Endocrinological Investigation

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 6 of the 11 sources its claims cite were checked for support.

Abstract

Purpose: Randomized controlled trials with tirzepatide (TZP) displayed unprecedented glucose and body weight lowering efficacy in individuals with type 2 diabetes and/or obesity and a safety profile similar to that of glucagon-like peptide-1 receptor agonists (GLP-1RA), mainly characterized by gastrointestinal (GI) adverse events (AE). Concerns on diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were also addressed. We aimed to investigate whether the same safety issues emerged from the FDA Adverse Event Reporting System (FAERS) post-marketing surveillance database. Methods: OpenVigil 2.1-MedDRA-v24 and AERS Mine (data 2004Q1-2023Q3) were used to query the FAERS database. Reports of GI AE, diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were investigated. The analysis was then filtered for age, gender, and designation as primary suspect. AE occurrence with TZP was compared to insulin, sodium-glucose cotransporter-2 inhibitors, metformin, and GLP-1RA. Results: Disproportionate reporting of GI [i.e., nausea (ROR 4.01, 95% CI 3.85–4.19)] and pancreato-biliary disorders [i.e., pancreatitis (ROR 3.63, 95% CI 3.15–4.19)], diabetic retinopathy (ROR 4.14, 95% CI 2.34–7.30), and medullary thyroid cancer (ROR 13.67, 95% CI 4.35–42.96) was detected. TZP exhibited a similar risk of GI AE and medullary thyroid cancer and a lower risk of most pancreato-biliary AE and diabetic retinopathy vs. GLP-1RA. Conclusions: TZP was associated with an increased risk of specific AE. However, its safety profile was similar to that of GLP-1RA, without increased risk of pancreato-biliary AE, diabetic retinopathy, and medullary thyroid cancer.

Overview

CoChat Summary

TL;DR

This FAERS pharmacovigilance analysis found disproportionate reporting of gastrointestinal, pancreato-biliary, diabetic retinopathy, and medullary thyroid cancer adverse events with tirzepatide. Overall, tirzepatide’s safety profile was similar to GLP-1 receptor agonists, with no increased risk of pancreatitis, diabetic retinopathy, or medullary thyroid cancer relative to that class.

Key findings

  • Tirzepatide was associated with 20,409 reports related to 1,432 adverse events; 116 fulfilled Evans’ criteria, including 44 administration site/procedural complications, 20 gastrointestinal disorders, and 14 nutrition/metabolism disorders.
  • Disproportionate gastrointestinal reporting included nausea (ROR 4.01, 95% CI 3.85–4.19), pancreatitis (ROR 3.63, 95% CI 3.15–4.19), impaired gastric emptying (ROR 13.3, 95% CI 10.7–16.7), and eructation (ROR 30.25, 95% CI 27.38–33.42).
  • Positive signals were also detected for diabetic retinopathy (ROR 4.13, 95% CI 2.34–7.29) and medullary thyroid cancer (ROR 13.67, 95% CI 4.35–42.96), though the latter was based on only 3 events.
  • Versus GLP-1RA as a class, tirzepatide showed similar risk of gastrointestinal adverse events and medullary thyroid cancer, and lower risk of most pancreato-biliary adverse events and diabetic retinopathy; it had lower risk of nausea and vomiting but greater risk of constipation, eructation, and gastrointestinal disorder.

Methods

  • FAERS was queried using OpenVigil 2.1-MedDRA-v24 and AERSMine for data from 2004Q1 to 2023Q3.
  • A positive disproportionality signal used Evans’ criteria: PRR ≥2, chi-squared ≥4, and ≥3 cases; reports were retrieved by MedDRA high level terms for gastrointestinal, pancreato-biliary, diabetic ophthalmic, and thyroid events.
  • Analyses compared tirzepatide with all other drugs, insulin, SGLT-2 inhibitors, metformin, and GLP-1RA, with filtering for age, gender, and primary suspect designation, plus sensitivity analyses excluding concomitant insulin or GLP-1RA use.

Limitations

  • The paper states that FAERS contains spontaneous reports without necessarily implying cause-effect; reporters include healthcare professionals, patients, families, representatives, and manufacturers, which can lead to duplicates and incomplete reporting, with dose, indication, gender, and age often missing.
  • The paper also states that reporting may be affected by public awareness, ethnicity, geography, and timing of approval/market introduction; oral versus injectable semaglutide and daily versus weekly exenatide could often not be distinguished; and data cover approximately the first 16 months of tirzepatide availability on the U.S. market.
  • Evident from the text: gender was missing in approximately 2,900 reports and age in approximately 13,000 reports, and some key signals relied on very few events (12 diabetic retinopathy events; 3 medullary thyroid cancer events), limiting precision.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40618-024-02441-z

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Disproportionately reported adverse events (AE) of interest for tirzepatide vs. all other drugs in the FAERS database. The forest plot shows reporting odds ratios (ROR) with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. control drugs
Fig. 1 Disproportionately reported adverse events (AE) of interest for tirzepatide vs. all other drugs in the FAERS database. The forest plot shows reporting odds ratios (ROR) with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. control drugsCC BY · PubMed Central
Fig. 2 Reporting odds ratio (ROR) of adverse events (AE) of interest for tirzepatide vs. all other drugs in females vs. males. The forest plot shows ROR with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. control drugs in females vs. males. A ROR < 1.0 indicates a disproportional lower rate of AE among reports for females
Fig. 2 Reporting odds ratio (ROR) of adverse events (AE) of interest for tirzepatide vs. all other drugs in females vs. males. The forest plot shows ROR with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. control drugs in females vs. males. A ROR < 1.0 indicates a disproportional lower rate of AE among reports for femalesCC BY · PubMed Central
Fig. 3 Reporting odds ratio of adverse events (AE) of interest for tirzepatide vs. all other drugs in individuals aged > 65 vs. 18–65 years. The forest plot shows reporting odds ratios (ROR) with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. control drugs in individuals aged > 65 years (old) vs. individuals aged 18–65 years (young). A ROR < 1.0 indicates a disproportional lower rate of AE among reports for individuals aged > 65 years
Fig. 3 Reporting odds ratio of adverse events (AE) of interest for tirzepatide vs. all other drugs in individuals aged > 65 vs. 18–65 years. The forest plot shows reporting odds ratios (ROR) with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. control drugs in individuals aged > 65 years (old) vs. individuals aged 18–65 years (young). A ROR < 1.0 indicates a disproportional lower rate of AE among reports for individuals aged > 65 yearsCC BY · PubMed Central
Fig. 4 Reporting odds ratio (ROR) of adverse events (AE) of interest for tirzepatide vs. all glucagon-like peptide-1 receptor agonists (GLP-1RA, A), semaglutide (B), insulin (C), sodium-glucose cotransporter-2 inhibitors (SGLT-2i, D). The forest plot shows ROR with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. all GLP-1RA (A), semaglutide (B), insulin (C), and SGLT-2i (D). A ROR < 1.0 indicates a disproportional lower rate of AE among reports for tirzepatide
Fig. 4 Reporting odds ratio (ROR) of adverse events (AE) of interest for tirzepatide vs. all glucagon-like peptide-1 receptor agonists (GLP-1RA, A), semaglutide (B), insulin (C), sodium-glucose cotransporter-2 inhibitors (SGLT-2i, D). The forest plot shows ROR with 95% confidence intervals for gastrointestinal, pancreato-biliary, eye-related, and thyroid-related AE for tirzepatide vs. all GLP-1RA (A), semaglutide (B), insulin (C), and SGLT-2i (D). A ROR < 1.0 indicates a disproportional lower rate of AE among reports for tirzepatideCC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 6 Not checked · 43 Own results and interpretations

35 more claims

Create a free account to see all 55 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 35 references

Cited by

See all 49

Metadata

Authors
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F.
Affiliations
University of Bari Aldo Moro (IT)
Corresponding author
Giorgino, F.
Venue
Journal of Endocrinological Investigation
Published
2024-08-14
Volume
47
Issue
11
Pages
2671-2678
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
OpenAlex
W4401575552
Cited by
49
References
35
Citations by year
2026: 15 · 2025: 32 · 2024: 2
FWCI
11.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Endocrinological Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Funders
  • National Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society”.
  • Università degli Studi di Bari Aldo Moro
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, drug safety, adverse events, type 2 diabetes, obesity, GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, pancreatitis, diabetic retinopathy, medullary thyroid carcinoma, post-marketing surveillance, FDA Adverse Event Reporting System
MeSH terms
Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Thyroid Neoplasms, United States, United States Food and Drug Administration, Databases, Factual, Adverse Drug Reaction Reporting Systems, Carcinoma, Neuroendocrine, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. https://app.cochat.ai/papers/10.1007/s40618-024-02441-z
The paper
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024). The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02441-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.